By 2032, the Ankylosing Spondylitis Treatment Market is expected to be worth US$ 5.1409 billion. Through 2032, the market for treating ankylosing spondylitis is expected to grow at a CAGR of 4.6%. By 2022, the market for ankylosing spondylitis treatment is expected to be worth US$ 8.06 billion. The market for treating ankylosing spondylitis is expected to be dominated by North America.
The global ankylosing spondylitis treatment market will continue to grow steadily, propelled by a slew of disparate but interconnected factors. Future Market Insights, an ESOMAR-certified market research firm, has released a new report that provides insightful insights on key factors that will influence growth through 2030.
Get a Sample Copy of the Report :
https://www.futuremarketinsights.com/reports/sample/rep-gb-12345
According to FMI’s report, the options for treatment include disease-modifying anti-rheumatic drugs (methotrexate), nonsteroidal anti-inflammatory drugs (naproxen, ibuprofen, celecoxib, meloxicam, and diclofenac), biologics (certolizumab pegol, secukinumab, infliximab), and biosimilars.
Key Takeaways from Ankylosing Spondylitis Treatment Market Study:
- Nonsteroidal anti-inflammatory drugs lead the market as they are looked upon as the first line of treatment for ankylosing spondylitis
- Oral route of administration holds the largest market share due to simplicity of consumption.
- By age group, “adults” contribute to majority of revenue generation as ankylosing spondylitis usually gets initiated in adulthood.
- North America, led by the US, holds the highest market share due to well-established healthcare infrastructure, high incidences of ankylosing spondylitis, and innovations in pharmaceutical industry.
Ankylosing Spondylitis Treatment Market Landscape:
The major players in the ankylosing spondylitis market
- Wyeth,
- Mitsubishi Tanabe,
- Schering-Plough,
- Takeda,
- Novartis AG,
- Amgen,
- Centocor,
- Abbott,
- Eisai,
As per the Oxford University Press, around 1% of the US population, 1.3-1.56 Mn European population, and 4.63-4.98 Mn population in the Asia Pacific are affected by ankylosing spondylitis. Also, the market is witnessing massive investment on the part of research to table new formulations.
Inorganic growth parameters are also contributing a great deal to the growth of ankylosing spondylitis treatment market. For instance – Novartis AG, in Jan 2019, entered into a collaboration with TrialSpark with an objective of increasing patients’ access to the clinical trials. The enrollment timeline is expected to shorten, thereby speeding up development of novel therapies.
In Oct 2019, the European Commission approved Cosentyx to treat non-radiographic axial spondyloarthritis. The next step includes submission of label update application to US FDA and post approval, the market is expected to grow substantially.
“Agreement” is the other strategy used. For instance – Izana Bioscience, in Dec 2017, entered into a global license agreement with Takeda Pharmaceutical Company for manufacturing, commercializing, and developing Namilumab to treat ankylosing spondylitis.
Also, Zydus Cadila, in Nov 2017, launched Adalimumab’s biosimilar in India. It has been used to treat ankylosing spondylitis, rheumatoid arthritis, juvenile idiopathic arthritis. Initiatives like these have been giving impetus to the ankylosing spondylitis market and the status quo is likely to remain the same in the forecast period.
Want More Insights?
The global ankylosing spondylitis treatment market is elaborated on the basis of drug class (Nonsteroidal Anti-inflammatory Drugs, Anti-Inflammatory Drugs, Immunosuppressive Drugs, TNF Blockers, JAK Inhibitors, Steroids, Biologics, and Others), route of administration (parenteral, oral), application (Adults, juvenile), and geography (North America, Latin America, Europe, East Asia, South Asia, Oceania, MEA).
Unlock Tailored Insights: Customize Your Report for Maximum Impact:https://www.futuremarketinsights.com/customization-available/rep-gb-12345
Key Segment:
Drug Class:
- Nonsteroidal Anti-inflammatory Drugs
- Anti-Inflammatory Drugs
- Immunosuppressive Drugs
- TNF Blockers
- JAK Inhibitors
- Steroids
- Biologics
- Others
Route of Administration:
- Parenteral
- Oral
Application:
- Adults
- Juveniles
Author By:
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
